3-D Matrix 7777.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 7777.T. It has been listed since 24 October 2011. In the fiscal year to 30 April 2026, it reported revenue of ¥10.89bn and net income of ¥4.16bn. At that date it held total assets of ¥9.80bn and shareholders' equity of ¥6.80bn.

3-D Matrix Ltd. engages in the research and development, manufacture, and sale of medical products. The company is headquartered in Chiyoda-Ku, Tokyo-To. The company went IPO on 2011-10-24. The firm has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Keiji NaganoChairman of the Board, since 2004
• Mr. Jun OkadaPresident, Representative Director, since 2007
• Mr. Toshi AmanumaExecutive Officer, Senior Director of North American Business, Director, since 2019
• Mr. Satoru KobayashiExecutive Officer, Director of Business Development, Director, since 2021
• Mr. Marie BufferExecutive Officer
• Mr. Andy KimExecutive Officer
• Mr. Kazuya ShimamuraIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.